Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16788111 | 0.82 | HRH3 (0.41) | HRH3KDM4EDRD2DRD3 | |
| SCHEMBL18664004 | 0.80 | HRH3 (0.41) | HRH3KDM4EDRD2DRD3 | |
| SCHEMBL18615952 | 0.79 | KDM1A (0.35) | HRH3 | |
| SCHEMBL24837354 | 0.79 | KDM1A (0.35) | HRH3 | |
| SCHEMBL8285972 | 0.77 | SIGMAR1 (0.44) | HRH3KDM4E | |
| SCHEMBL21414332 | 0.77 | HRH3 (0.41) | HRH3KDM4EDRD2DRD3 | |
| SCHEMBL19860547 | 0.77 | SIGMAR1 (0.44) | HRH3KDM4E | |
| SCHEMBL3532818 | 0.77 | HRH3 (0.39) | HRH3KDM4E | |
| SCHEMBL23114309 | 0.76 | SHBG (0.41) | HRH3KDM4E | |
| SCHEMBL20240029 | 0.76 | HRH3 (0.41) | HRH3KDM4EDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358936-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20210171465-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358936-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | LOXL2, LOXL1, LOX | HRH3 3039/4885KDM4E 1498/4885DRD2 4268/4885 |
| US-20210171465-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | HRH3 3039/4885KDM4E 1498/4885DRD2 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.